InvestorWire NewsRoom


XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track
June 30, 2021

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

  • XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule”
  • The program, which started in early 2021, is slated for completion in late Q3 2021
  • The first initial production batches were completed successfully, marking a significant milestone for the program
  • Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021 ( So far, the company has completed the production of the initial batches and streamlined operations in readiness for scaling Its current focus is on the growth of production capability and the development of analytical methods of validation. 

“With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto’s psychedelic medicine program is progressing on schedule. As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation,” said Hugh Rogers, XPhyto’s CEO ( 

Back in early 2021, XPhyto announced its move to focus its resources and expertise on using active pharmaceutical ingredients for neurological application. These included psychedelic compounds, such as mescaline and psilocybin, and cannabinoids. The two psychedelic compounds form critical components in the company’s psychedelic medicine program, while working towards providing a foundation for its drug formulation and clinical validation work.

This Vancouver-based life sciences technology accelerator is known for constantly pushing the envelope in bioscience research, focusing on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities. So far, it has made considerable strides in precision transdermal and oral dissolvable drug formulations, the rapid, low-cost infectious disease and oral health screening tests and, most importantly, the standardization of emerging active pharmaceutical ingredients for neurological applications (

XPhyto is confident that mescaline can become the next frontier in the current ongoing psychedelics renaissance. It is a product that presents the opportunity to innovate and improve on existing methods of mental health therapy, having already proven effective in the treatment of mental health-related medical conditions that include, but are not limited to anxiety, depression, addiction and trauma-related stress disorder.

Mescaline is a naturally occurring psychedelic compound, typically found in specific cacti. In a recent publication by ACS Pharmacology and Translational Science, it was noted that the naturalistic use of mescaline is linked to psychiatric improvements and lasting positive life changes. It was further pointed out that its use among individuals with alcohol and drug use disorders (“AUD” and “DUD”), along with post-traumatic stress disorder (“PTSD”), all reported significant improvement following mescaline use and accompanying treatment ( 

With the current strides that XPhyto is making with its mescaline program, it is slowly laying the foundation for mental health therapy and the treatment of various mental health-related conditions. Additionally, it further plays a more significant role in sensitizing society on the usefulness and potential of psychedelic compounds and cannabinoids. XPhyto is also serving as proof of the financial viability of pharmaceutical-grade psychedelics and their use in treating psychological illnesses.

“We see a significant market opportunity in the production of pharmaceutical-grade psychedelics followed by the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” Hugh mentioned.

Currently, XPhyto has development operations in North America and Europe and an operational focus in Germany. As it focuses on scaling up its production capability, the company is also working on developing standard operating procedures (“SOP”) for GMP certification of its synthesis process.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).